Laboratory of Pharmacology, Osaka University of Pharmaceutical Sciences.
Biol Pharm Bull. 2013;36(9):1396-400. doi: 10.1248/bpb.b13-00310.
The serotonergic nervous system plays crucial roles in regulating psycho-emotional, cognitive, sensori-motor and autonomic functions. It is now known that multiple serotonin (5-hydroxytryptamine; 5-HT) receptors regulate extrapyramidal motor functions, which are implicated in pathogenesis and/or treatment of various neurological disorders (e.g., Parkinson's disease and drug-induced extrapyramidal motor deficits). Specifically, antagonism of 5-HT2A/2C receptors alleviates antipsychotic-induced extrapyramidal side effects (EPS) by relieving the 5-HT2A/2C receptor-mediated inhibition of nigral dopaminergic neuron activity and striatal dopamine release. Indeed, many of the second generation antipsychotics (e.g., risperidone, perospirone and olanzapine) commonly possess potent 5-HT2A/2C blocking actions which contribute to their atypical antipsychotic property. In addition, activation of 5-HT1A receptors also improves antipsychotic-induced EPS and motor disabilities in animal models of Parkinson's disease. Microinjection studies revealed that stimulation of postsynaptic 5-HT1A receptors in the striatum or motor cortex plays an important role in the antiparkinsonian actions. Furthermore, recent studies demonstrated that antagonism of 5-HT3 and 5-HT6 receptors alleviates extrapyramidal motor disorders while 5-HT4, 5-HT5, and 5-HT7 receptors are mostly inactive. These results encourage drug discovery research into new 5-HT receptor ligands that could improve current therapies for extrapyramidal motor disorders.
5-羟色胺能神经系统在调节心理情绪、认知、感觉运动和自主功能方面起着至关重要的作用。现在已经知道,多种 5-羟色胺(5-羟色胺;5-HT)受体调节锥体外系运动功能,这些功能与各种神经疾病(如帕金森病和药物引起的锥体外系运动功能障碍)的发病机制和/或治疗有关。具体来说,5-HT2A/2C 受体拮抗剂通过缓解 5-HT2A/2C 受体介导的黑质多巴胺能神经元活动和纹状体多巴胺释放抑制,减轻抗精神病药引起的锥体外系副作用(EPS)。事实上,许多第二代抗精神病药(如利培酮、哌罗匹隆和奥氮平)通常具有很强的 5-HT2A/2C 阻断作用,这有助于它们具有非典型抗精神病特性。此外,5-HT1A 受体的激活也改善了帕金森病动物模型中抗精神病药引起的 EPS 和运动障碍。微注射研究表明,纹状体或运动皮层中突触后 5-HT1A 受体的刺激在抗帕金森作用中起着重要作用。此外,最近的研究表明,5-HT3 和 5-HT6 受体拮抗剂缓解锥体外系运动障碍,而 5-HT4、5-HT5 和 5-HT7 受体大多没有活性。这些结果鼓励开展新的 5-HT 受体配体的药物发现研究,以改善目前针对锥体外系运动障碍的治疗方法。